Insider buying last 90 days
No open-market insider purchases were filed for GKOS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GKOS insider filing, plotted on the chart in Gekko.Open GKOS in Gekko
NYSE: GKOS
Glaukos (GKOS) Stock Analysis & Forecast
Sep 28 close
$158.56+4.13 (+2.7%)
Gekko Brief
AI summaryGlaukos shares this week reflect a mix of insider selling and product-related news. Chief Development Officer Tomas Navratil sold $249,158 worth of stock under a Rule 10b5-1 plan, alongside a related Form 144 filing, though this followed the vesting of restricted shares dated March 22, 2025. Separately, the company launched a keratoconus-awareness campaign with Stephen Curry, and options activity has pointed to a bullish call spread targeting $180 by October 16, 2026, built from buying $160 calls and selling $180 calls.
The stock closed at $158.56, up 2.7%, sitting between its 50-day average of $171.27 and 200-day average of $133.98, indicating a mixed trend. The GekkoIndex reads 68.2, placing it in the Accumulation zone. Price sits 13% below Gekko Fair Value of $182.24, a gap that bears watching. Over the past year the stock has returned 94.6%, though the past month shows a decline of 12.8%.
Over the next 20 trading days, the next earnings report is due 4 November 2026, outside that window. In the last 30 days, 2 unusual options signals have been recorded, with call premium of $708,621 against put premium of $954,720. Seasonality over 5 years shows an average 20-day return of -4.3% from this point in the calendar, with gains in 2 of those years. Analyst coverage from 13 firms shows 12 buy ratings and 1 hold, with a consensus target of $198.69.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Glaukos price vs fair value
Close $158.56200-day averageGekko Fair Value $182.24
Glaukos quick facts
- Market cap
- $9.35B
- P/E ratio
- —
- Forward P/E
- 1,666.7
- EPS, TTM
- −$3.27
- Revenue, TTM
- $612.8M
- Profit margin
- -30.7%
- Dividend yield
- —
- Beta
- 0.77
- Volume
- 1.32M avg 817,979
- 1-year return
- +94.6%
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±8.2%
- 50-day average
- $171.27
- 200-day average
- $133.98
- Next earnings
- Nov 4 after close
- Shares outstanding
- 58.98M
Glaukos swing-trade checklist
Glaukos scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $158.56 sits between the 50-day ($171.27) and 200-day ($133.98) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
68.2, Accumulation
Reading 68.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
13.0% below
Price is 13% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 2 unusual options signals.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.3% on average
From this point in the calendar, the next 20 trading days averaged −4.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Glaukos stock chart and price history
Glaukos closed at $158.56 on Sep 28, 2026, +94.6% over the past year, inside a 52-week range of $73.16 to $191.62.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.8%
- 3 months
- +11.5%
- 6 months
- +53.7%
- 1 year
- +94.6%
The full GKOS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GKOS in Gekko
Follow Glaukos through every session
Put GKOS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GKOS in GekkoFree for 7 days. No credit card required.
About Glaukos
Glaukos develops medical devices and pharmaceutical products for eye conditions, with particular attention to glaucoma along with corneal and retinal disorders. It is best recognized for its micro-bypass stent line, including iStent, iStent inject, and iStent inject W, small devices implanted during cataract surgery to help fluid drain from the eye and ease mild-to-moderate open-angle glaucoma. Beyond these established products, the company is advancing iStent Infinite, a three-stent option meant to be used on its own for harder-to-treat glaucoma cases, and iDose TR, an implant built on its micro-scale technology that delivers medication directly to the eye over time.
Glaukos reaches physicians and patients through its own sales force as well as outside distributors, with sales spanning both domestic and international markets.
The company was founded in 1998 and is based in San Clemente, California. Its shares trade on the NYSE under the ticker GKOS.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- glaukos.com
Glaukos GekkoIndex: the smart money zone
Glaukos’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.2, in the Accumulation zone, up 0.4 points over five sessions.
68.2Accumulation
Up 0.4 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 31 | +0.4% | +4.0% | ||
| Accumulation (current zone) | 153 | +1.0% | +3.4% | ||
| Neutral | 434 | +0.5% | +2.6% | ||
| Distribution | 48 | +0.8% | −0.5% | ||
| Selling | 6 | Too few readings yet | |||
Average GKOS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the GKOS price, zone by zone.Track GKOS in Gekko
Is Glaukos stock overvalued? Gekko Fair Value
Glaukos trades 13.0% below Gekko Fair Value of $182.24, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Glaukos shares are worth, recalculated every trading day.
$182.24
Gekko Fair Value, Sep 29, 2026
13.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open GKOS in Gekko
Glaukos insider and Congress trading
No open-market insider purchases were filed for Glaukos, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GKOS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GKOS, plotted on the chart in Gekko.Open GKOS in Gekko
Buybacks
Glaukos has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $2.79M
- As a share of market cap
- 0.03%
From company filings.
Unusual options activity last 30 days
2signals, 43% of the flagged premium in calls.
Latest: Bullish flow on Sep 29, $709K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds GKOS.
0added1opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Glaukos earnings: next date and track record
Glaukos reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- −$0.12
- Revenue estimate
- $167.9M
6 of 8reports beat the EPS estimate
±12.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Glaukos reported a strong Q2 2026 with record consolidated net sales of $185.6 million, up ~50% year-over-year, driven by robust performance in its U.S. glaucoma franchise and early commercial traction for Epioxa. Management raised full-year 2026 net sales guidance to $680M–$700M (up $60M–$65M) and provided product-level commentary including iDose TR sales (~$74M in Q2) and expectations for iDose full-year revenue in the $275M–$285M range. Key growth drivers cited were iDose TR and Epioxa; the company emphasized continued investment in commercial infrastructure and R&D (including clinical programs and future corneal product generations). Management noted some short-term headwinds and transition-related volatility (notably the transition to a permanent J-code for Epioxa and certain international reimbursement pressures), but expressed confidence in longer-term market opportunity and the company’s ability to drive sustained growth and margin expansion.
- Guidance
- Raised full-year 2026 net sales guidance to $680 million to $700 million (from $620M–$635M). iDose full-year revenue expectation: $275 million to $285 million. Gross margin guidance maintained at 84%–86% for the year. Operating expenses expected to land around $600 million for the year. International glaucoma growth expected low-to-mid teens for the year. Corneal Health growth referenced around ~20% year-over-year (subject to Q3 transition volatility).
- Risks flagged
- Near-term volatility from the transition to the permanent J-code for Epioxa (potential Q3 air pocket and reset of prior authorization/contracting processes). Uncertainty around regional reimbursement (noted pressures in Germany and Switzerland) and ongoing MAC/LCD developments for iDose (draft LCD and potential final LCD outcomes). FX headwinds abating (less tailwind than prior periods). General execution risks associated with new product launches, payer adoption, prior authorization/backlog timing, and competitive entrants in corneal cross-linking.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | −$0.14 est −$0.28 | $185.6M est $150.9M | +11.4% |
| Apr 29, 2026 | −$0.18 est −$0.28 | $150.6M est $137.0M | +20.1% |
| Feb 17, 2026 | −$0.28 est −$0.22 | $143.1M est $136.4M | +10.5% |
| Oct 29, 2025 | −$0.16 est −$0.27 | $133.5M est $129.5M | +12.9% |
| Jul 30, 2025 | −$0.24 est −$0.26 | $124.1M est $122.4M | −8.2% |
| Apr 30, 2025 | −$0.22 est −$0.35 | $106.7M est $102.8M | −11.0% |
| Feb 20, 2025 | −$0.40 est −$0.39 | $105.5M est $101.0M | −21.6% |
| Nov 4, 2024 | −$0.28 est −$0.48 | $96.67M est $100.5M | −3.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Glaukos stock forecast and analyst price targets
Analysts’ average 12-month price target for Glaukos is $198.69, +25.3% from the last close, from 13 firms rating the stock in the last 90 days.
$198.69consensus 12-month target, +25.3% from the last close
Now $158.56Avg $198.69
Low $172High $225
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 22 | Jefferies | $210 | +32.4% |
| Sep 4 | Stifel Nicolaus | $190 | +19.8% |
| Aug 20 | BTIG | $202 | +27.4% |
| Aug 14 | Citi | $225 | +41.9% |
| Aug 13 | Citi | $225 | +41.9% |
+3.4%average 20-day move after past Accumulation readings
−4.3%average move over the next 20 trading days in the last 5 years
±4.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Glaukos seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Glaukos averaged −4.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.8% | 3 of 5 |
| Next 10 trading days | −3.2% | 1 of 5 |
| Next 15 trading days | −2.3% | 2 of 5 |
| Next 20 trading days | −4.3% | 2 of 5 |
| Next 30 trading days | +0.1% | 3 of 5 |
For scale, GKOS’s typical 20-trading-day move in either direction is about 8.2%.
Glaukos market cap and key statistics
Glaukos’s market cap is $9.35B and revenue of $612.8M over the last twelve months.
Valuation
- Market cap
- $9.35B
- Forward P/E
- 1,666.7
- EPS, TTM
- −$3.27
- Gekko Fair Value
- $182.24
Trading
- Volume
- 1.32M
- Avg volume, 20 days
- 817,979
- 52-week high
- $191.62
- 52-week low
- $73.16
- Shares outstanding
- 58.98M
Financials
- Revenue, TTM
- $612.8M
- Profit margin
- -30.7%
- Return on equity
- -26%
- Quarterly earnings growth, YoY
- +1,896.0%
Risk and income
- Beta
- 0.77
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±8.2%
Glaukos stock news this week
Coverage of Glaukos this week reads positive: 3 positive, 3 neutral and 2 negative headlines.
- Glaukos chief development officer sells $249k in stock By Investing.comInvesting.com India, Sep 29
- Glaukos (GKOS) officer sells shares under a preset plan at weighted-average prices from $151.70 to $154.88Stock Titan, Sep 28
- Glaukos options activity points to bullish call spread targeting $180Investing.com, Sep 28
- Form 144 GLAUKOS Corp For: 26 September By Investing.comInvesting.com India, Sep 26
- A Glaukos (NYSE: GKOS) officer proposes selling 1,615 shares on September 25.Stock Titan, Sep 25
- Here's Why You Should Retain Glaukos Stock in Your Portfolio for NowZacks Investment Research, Sep 24
Glaukos peers
Glaukos’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Glaukos stock FAQ
What is Glaukos’s market cap?
Glaukos’s market cap is $9.35B at the Sep 28, 2026 close of $158.56, with 58.98M shares outstanding.
What is the Glaukos stock forecast?
The consensus analyst 12-month price target for Glaukos is $198.69, +25.3% from the last close. Of the 13 firms that rated the stock in the last 90 days, 12 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Glaukos stock overvalued or undervalued?
On Gekko’s estimate Glaukos is undervalued: the Sep 28, 2026 close of $158.56 is 13.0% below Gekko Fair Value of $182.24. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Glaukos report earnings next?
Glaukos is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of −$0.12 per share on revenue of $167.9M. Glaukos beat the earnings estimate in 6 of its last 8 reports, moving 12.3% on average across the report.
What is Glaukos’s 52-week high and low?
Glaukos’s 52-week high is $191.62 and its 52-week low is $73.16; it closed at $158.56 on Sep 28, 2026, +94.6% over the past year.
Is Glaukos stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 2 as headwinds (smart money and seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Glaukos?
Gekko flagged 2 unusual options signals in Glaukos over the last 30 days, with $709K of flagged premium in calls and $955K in puts. The latest, bullish flow, was on Sep 29, 2026 with $709K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Glaukos the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.